Skip to content

US · DSGN · BIOTECHNOLOGY

Design Therapeutics, Inc. (DSGN) intrinsic value and stock valuation

$9.02as of 2026-11-21 · Mkt cap 847.54M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Design Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values DSGN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from DSGN’s statements →

Design Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Carlsbad, CA 92011 designtx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-69.79M
20192025
Free cash flow
-$-54.55M
20192025
Total equity
$212.5M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-79.47M-$-62.38M-$-78.19M-$-67.59M-$-35.83M
Net income-$-69.79M-$-49.59M-$-66.86M-$-63.31M-$-35.53M
EPSd-$-1.22M-$-876.3K-$-1.19M-$-1.14M-$-773.4K
Operating cash flow-$-54.36M-$-43.1M-$-58.56M-$-51.32M-$-29.38M
Capital expenditure-$-190K-$-340K-$-260K-$-920K-$-1.54M
Free cash flow-$-54.55M-$-43.45M-$-58.82M-$-52.23M-$-30.91M
Total assets$226.2M$252.1M$289.6M$341.1M$390.6M
Total debt$1.53M$2.33M$3.05M$3.69M$3.63M
Net debt-$-15.32M-$-20.23M-$-18.15M-$-22.81M-$-294.94M
Total equity$212.5M$242.1M$277.7M$327.3M$382.1M
Cash and short-term investments$219.8M$245.5M$281.8M$330.4M$384.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$620K$600K$540K$470K$0.00
Gross profit-$-620K-$-600K-$-540K-$-470K$0.00
Research and development expenses$59.1M$44.4M$57.1M$48.6M$24.8M
Selling, general and administrative expenses$20.3M$18M$21.1M$19M$11.1M
Other expenses-$-620K-$-600K-$-540K-$-470K$0.00
Operating expenses$78.8M$61.8M$77.7M$67.1M$35.8M
Cost and expenses$79.5M$62.4M$78.2M$67.6M$35.8M
Interest income$9.68M$12.8M$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$620K$600K$540K$470K$130K
Ebitda-$-69.17M-$-48.99M-$-66.33M-$-62.84M-$-35.4M
Operating income-$-79.47M-$-62.38M-$-78.19M-$-67.59M-$-35.83M
Total other income/expenses, net$9.68M$12.8M$11.3M$4.29M$300K
Income before tax-$-69.79M-$-49.59M-$-66.86M-$-63.31M-$-35.53M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-69.79M-$-49.59M-$-66.86M-$-63.31M-$-35.53M
Weighted average shares outstanding$57.3M$56.6M$56M$55.7M$45.9M
Weighted average diluted shares outstanding$57.3M$56.6M$56M$55.7M$45.9M
Balance sheet
20252024202320222021
Cash and short-term investments$219.8M$245.5M$281.8M$330.4M$384.1M
Net receivables$1.68M$1.26M$1.43M$1.11M$110K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$223.8M$248M$284.6M$335.1M$385.4M
Property, plant and equipment, net$2.42M$3.63M$4.63M$5.56M$5.12M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$2.42M$4.05M$5.06M$6.02M$5.12M
Total assets$226.2M$252.1M$289.6M$341.1M$390.6M
Accounts payable$2.31M$2.19M$1.94M$3.02M$1.62M
Short-term debt$890K$800K$720K$640K$490K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$13.1M$8.46M$9.62M$10.8M$5.28M
Long-term debt$650K$1.53M$2.33M$3.05M$3.14M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$650K$1.53M$2.33M$3.05M$3.14M
Capital lease obligations$890K$2.33M$3.05M$3.69M$3.63M
Total liabilities$13.7M$10M$12M$13.8M$8.43M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-297.01M-$-227.21M-$-177.63M-$-110.76M-$-47.46M
Accumulated other comprehensive income (loss)$400K$470K$60K-$-3.36M-$-240K
Total equity$212.5M$242.1M$277.7M$327.3M$382.1M
Total investments$203M$222.9M$260.6M$303.9M$85.5M
Total debt$1.53M$2.33M$3.05M$3.69M$3.63M
Net debt-$-15.32M-$-20.23M-$-18.15M-$-22.81M-$-294.94M
Cash flow statement
20252024202320222021
Net income-$-69.79M-$-49.59M-$-66.86M-$-63.31M-$-35.53M
Depreciation and amortization$620K$600K$540K$410K$130K
Stock-based compensation$14.6M$13.1M$13.1M$10.9M$4.69M
Change in working capital$3.11M-$-990K$730K$1.99M$1.4M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$4.49M-$-1.22M-$-1.25M$5.38M$2.41M
Net cash provided by operating activities-$-54.36M-$-43.1M-$-58.56M-$-51.32M-$-29.38M
Investments in property, plant and equipment-$-190K-$-340K-$-260K-$-920K-$-1.54M
Acquisitions, net$0.00$0.00$0.00$40K$50K
Net cash used for investing activities$22.9M$44M$52.5M-$-220.99M-$-53.64M
Common stock issued$25.7M$510K$720K$660K$254.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$25.7M$510K$720K$230K$379.2M
Net change in cash-$-5.71M$1.36M-$-5.3M-$-272.07M$296.2M
Cash at end of period$16.9M$22.6M$21.2M$26.5M$298.6M
Operating cash flow-$-54.36M-$-43.1M-$-58.56M-$-51.32M-$-29.38M
Capital expenditure-$-190K-$-340K-$-260K-$-920K-$-1.54M
Free cash flow-$-54.55M-$-43.45M-$-58.82M-$-52.23M-$-30.91M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Design Therapeutics, Inc.

        Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.

        CEO
        Pratik Shah
        Employees
        124
        Beta
        1.59

        Explore

        Frequently asked questions

        What is the intrinsic value of Design Therapeutics, Inc. (DSGN)?

        InvestorsCraft does not currently publish an intrinsic value for DSGN. How the IC value is calculated.

        Is DSGN undervalued?

        InvestorsCraft does not publish an undervaluation signal for DSGN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.